首页 > 最新文献

Kidney International Supplements最新文献

英文 中文
Title Page 标题页
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2021-04-01 DOI: 10.1016/S2157-1716(21)00024-1
{"title":"Title Page","authors":"","doi":"10.1016/S2157-1716(21)00024-1","DOIUrl":"https://doi.org/10.1016/S2157-1716(21)00024-1","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"11 1","pages":"Page A7"},"PeriodicalIF":5.5,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(21)00024-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72053965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolving science of anemia management in chronic kidney disease 慢性肾脏疾病贫血管理科学的发展
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2021-04-01 DOI: 10.1016/j.kisu.2020.11.002
Ziad A. Massy , Tilman B. Drueke
{"title":"The evolving science of anemia management in chronic kidney disease","authors":"Ziad A. Massy , Tilman B. Drueke","doi":"10.1016/j.kisu.2020.11.002","DOIUrl":"10.1016/j.kisu.2020.11.002","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"11 1","pages":"Pages 1-2"},"PeriodicalIF":5.5,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2020.11.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25525346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease 缺氧诱导因子-脯氨酸羟化酶抑制剂治疗慢性肾病贫血
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2021-04-01 DOI: 10.1016/j.kisu.2020.12.002
Volker H. Haase

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising new class of orally administered drugs currently in late-stage global clinical development for the treatment of anemia of chronic kidney disease (CKD). HIF-PHIs activate the HIF oxygen-sensing pathway and are efficacious in correcting and maintaining hemoglobin levels in patients with non–dialysis- and dialysis-dependent CKD. In addition to promoting erythropoiesis through the increase in endogenous erythropoietin production, HIF-PHIs reduce hepcidin levels and modulate iron metabolism, providing increases in total iron binding capacity and transferrin levels, and potentially reducing the need for i.v. iron supplementation. Furthermore, HIF-activating drugs are predicted to have effects that extend beyond erythropoiesis. This review summarizes clinical data from current HIF-PHI trials in patients with anemia of CKD, discusses mechanisms of action and pharmacologic properties of HIF-PHIs, and deliberates over safety concerns and potential impact on anemia management in patients with CKD.

低氧诱导因子-脯氨酸羟化酶结构域抑制剂(HIF-PHIs)是一种有前景的新型口服药物，目前在全球临床开发后期用于治疗慢性肾脏疾病(CKD)贫血。HIF- phis激活HIF氧感应途径，在非透析和依赖透析的CKD患者中有效地纠正和维持血红蛋白水平。除了通过增加内源性促红细胞生成素产生来促进红细胞生成外，HIF-PHIs还降低hepcidin水平并调节铁代谢，从而增加总铁结合能力和转铁蛋白水平，并可能减少静脉补铁的需求。此外，预计hif激活药物的作用将超出红细胞生成。本文综述了目前HIF-PHI在CKD贫血患者中的临床数据，讨论了HIF-PHI的作用机制和药理学特性，并讨论了HIF-PHI的安全性问题和对CKD患者贫血管理的潜在影响。
{"title":"Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","authors":"Volker H. Haase","doi":"10.1016/j.kisu.2020.12.002","DOIUrl":"10.1016/j.kisu.2020.12.002","url":null,"abstract":"<div><p>Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising new class of orally administered drugs currently in late-stage global clinical development for the treatment of anemia of chronic kidney disease (CKD). HIF-PHIs activate the HIF oxygen-sensing pathway and are efficacious in correcting and maintaining hemoglobin levels in patients with non–dialysis- and dialysis-dependent CKD. In addition to promoting erythropoiesis through the increase in endogenous erythropoietin production, HIF-PHIs reduce hepcidin levels and modulate iron metabolism, providing increases in total iron binding capacity and transferrin levels, and potentially reducing the need for i.v. iron supplementation. Furthermore, HIF-activating drugs are predicted to have effects that extend beyond erythropoiesis. This review summarizes clinical data from current HIF-PHI trials in patients with anemia of CKD, discusses mechanisms of action and pharmacologic properties of HIF-PHIs, and deliberates over safety concerns and potential impact on anemia management in patients with CKD.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"11 1","pages":"Pages 8-25"},"PeriodicalIF":5.5,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2020.12.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25525347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 67
Anemia of cardiorenal syndrome 心肾综合征贫血
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2021-04-01 DOI: 10.1016/j.kisu.2020.12.001
Peter A. McCullough

Cardiorenal syndrome includes a spectrum of disorders of the kidneys and heart in which loss of function in one organ contributes to reduced function in the other organ. Cardiorenal syndrome is frequently complicated by comorbid anemia, which leads to reciprocal and progressive cardiac and renal deterioration. The triad of heart failure, chronic kidney disease (CKD), and anemia is termed cardiorenal anemia syndrome (CRAS). There are currently no evidence-based recommendations for managing patients with CRAS; however, the treatment of these patients is multifactorial. Not only must the anemia be controlled, but heart failure and kidney injury must be addressed, in addition to other comorbidities. Intravenous iron and erythropoiesis-stimulating agents are the mainstays of treatment for anemia of CKD, addressing both iron and erythropoiesis deficiencies. Since erythropoiesis-stimulating agent therapy can be associated with adverse outcomes at higher doses in patients with CKD and is not used in routine practice in patients with heart failure, treatment options for managing anemia in patients with CRAS are limited. Several new therapies, particularly the hypoxia-inducible factor–prolyl hydroxylase inhibitors, are currently under clinical development. The hypoxia-inducible factor–prolyl hydroxylase inhibitors have shown promising results for treating anemia of CKD in clinical trials and may confer benefits in patients with CRAS, potentially addressing some of the limitations of erythropoiesis-stimulating agents. Updated clinical practice guidelines for the screening and management of anemia in cardiorenal syndrome, in light of potential new therapies and clinical evidence, would improve the clinical outcomes of patients with this complex syndrome.

心肾综合征包括一系列肾脏和心脏疾病，其中一个器官的功能丧失会导致另一个器官的功能下降。心肾综合征常并发共病性贫血，导致心脏和肾脏的相互和进行性恶化。心衰，慢性肾脏疾病(CKD)和贫血的三位一体被称为心肾性贫血综合征(CRAS)。目前尚无管理CRAS患者的循证建议;然而，这些患者的治疗是多因素的。不仅要控制贫血，还要解决心力衰竭和肾损伤，以及其他合并症。静脉注射铁和促红细胞生成素是治疗慢性肾病贫血的主要药物，可解决铁和红细胞生成素缺乏症。由于高剂量的促红细胞生成剂治疗可能与CKD患者的不良后果相关，并且不用于心力衰竭患者的常规实践，因此治疗CRAS患者贫血的治疗选择有限。一些新的治疗方法，特别是缺氧诱导因子-脯氨酸羟化酶抑制剂，目前正在临床开发中。在临床试验中，缺氧诱导因子-丙氨酸羟化酶抑制剂在治疗CKD贫血方面显示出良好的效果，并可能给CRAS患者带来益处，潜在地解决了一些促红细胞生成药物的局限性。鉴于潜在的新疗法和临床证据，更新心肾综合征贫血筛查和管理的临床实践指南将改善这一复杂综合征患者的临床结局。
{"title":"Anemia of cardiorenal syndrome","authors":"Peter A. McCullough","doi":"10.1016/j.kisu.2020.12.001","DOIUrl":"10.1016/j.kisu.2020.12.001","url":null,"abstract":"<div><p>Cardiorenal syndrome includes a spectrum of disorders of the kidneys and heart in which loss of function in one organ contributes to reduced function in the other organ. Cardiorenal syndrome is frequently complicated by comorbid anemia, which leads to reciprocal and progressive cardiac and renal deterioration. The triad of heart failure, chronic kidney disease (CKD), and anemia is termed cardiorenal anemia syndrome (CRAS). There are currently no evidence-based recommendations for managing patients with CRAS; however, the treatment of these patients is multifactorial. Not only must the anemia be controlled, but heart failure and kidney injury must be addressed, in addition to other comorbidities. Intravenous iron and erythropoiesis-stimulating agents are the mainstays of treatment for anemia of CKD, addressing both iron and erythropoiesis deficiencies. Since erythropoiesis-stimulating agent therapy can be associated with adverse outcomes at higher doses in patients with CKD and is not used in routine practice in patients with heart failure, treatment options for managing anemia in patients with CRAS are limited. Several new therapies, particularly the hypoxia-inducible factor–prolyl hydroxylase inhibitors, are currently under clinical development. The hypoxia-inducible factor–prolyl hydroxylase inhibitors have shown promising results for treating anemia of CKD in clinical trials and may confer benefits in patients with CRAS, potentially addressing some of the limitations of erythropoiesis-stimulating agents. Updated clinical practice guidelines for the screening and management of anemia in cardiorenal syndrome, in light of potential new therapies and clinical evidence, would improve the clinical outcomes of patients with this complex syndrome.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"11 1","pages":"Pages 35-45"},"PeriodicalIF":5.5,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2020.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25525798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Subscription Information 订阅信息
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2020-12-01 DOI: 10.1016/S2157-1716(20)30025-3
{"title":"Subscription Information","authors":"","doi":"10.1016/S2157-1716(20)30025-3","DOIUrl":"https://doi.org/10.1016/S2157-1716(20)30025-3","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 2","pages":"Page A2"},"PeriodicalIF":5.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(20)30025-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72026893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Tonelli M, Nkunu V, Varghese C, et al. Framework for establishing integrated kidney care programs in low- and middle-income countries” Kidney Int Suppl. 2020;10:e19–e23 “Tonelli M，Nkunu V，Varghese C等人在中低收入国家建立综合肾脏护理计划的框架”肾脏国际增刊2020的勘误表；10:e19–e23
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2020-12-01 DOI: 10.1016/j.kisu.2020.11.001
Marcello Tonelli , Victoria Nkunu , Cherian Varghese , Ali K. Abu-Alfa , Mona N. Alrukhaimi , Bassam Bernieh , Louise Fox , John Gill , David C.H. Harris , Fan Fan Hou , Philip J. O’Connell , Harun Ur Rashid , Abdou Niang , Shahrzad Ossareh , Vladimir Tesar , Elena Zakharova , Chih-Wei Yang
{"title":"Corrigendum to “Tonelli M, Nkunu V, Varghese C, et al. Framework for establishing integrated kidney care programs in low- and middle-income countries” Kidney Int Suppl. 2020;10:e19–e23","authors":"Marcello Tonelli ,&nbsp;Victoria Nkunu ,&nbsp;Cherian Varghese ,&nbsp;Ali K. Abu-Alfa ,&nbsp;Mona N. Alrukhaimi ,&nbsp;Bassam Bernieh ,&nbsp;Louise Fox ,&nbsp;John Gill ,&nbsp;David C.H. Harris ,&nbsp;Fan Fan Hou ,&nbsp;Philip J. O’Connell ,&nbsp;Harun Ur Rashid ,&nbsp;Abdou Niang ,&nbsp;Shahrzad Ossareh ,&nbsp;Vladimir Tesar ,&nbsp;Elena Zakharova ,&nbsp;Chih-Wei Yang","doi":"10.1016/j.kisu.2020.11.001","DOIUrl":"https://doi.org/10.1016/j.kisu.2020.11.001","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 2","pages":"Page e186"},"PeriodicalIF":5.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2020.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72026895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription Information 订阅信息
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2020-12-01 DOI: 10.1016/s2157-1716(20)30025-3
{"title":"Subscription Information","authors":"","doi":"10.1016/s2157-1716(20)30025-3","DOIUrl":"https://doi.org/10.1016/s2157-1716(20)30025-3","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"22 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77684286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page 标题页
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2020-12-01 DOI: 10.1016/s2157-1716(20)30026-5
{"title":"Title Page","authors":"","doi":"10.1016/s2157-1716(20)30026-5","DOIUrl":"https://doi.org/10.1016/s2157-1716(20)30026-5","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"80 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83962090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
China Kidney Disease Network (CK-NET) 2016 Annual Data Report 中国肾脏疾病网(CK-NET) 2016年度数据报告
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2020-12-01 DOI: 10.1016/j.kisu.2020.09.001
Luxia Zhang (Chief Editor), Ming-Hui Zhao (Chief Editor), Li Zuo (Associate Editor), Yue Wang (Associate Editor), Feng Yu (Associate Editor), Hong Zhang (Associate Editor), Haibo Wang (Associate Editor)
{"title":"China Kidney Disease Network (CK-NET) 2016 Annual Data Report","authors":"Luxia Zhang (Chief Editor),&nbsp;Ming-Hui Zhao (Chief Editor),&nbsp;Li Zuo (Associate Editor),&nbsp;Yue Wang (Associate Editor),&nbsp;Feng Yu (Associate Editor),&nbsp;Hong Zhang (Associate Editor),&nbsp;Haibo Wang (Associate Editor)","doi":"10.1016/j.kisu.2020.09.001","DOIUrl":"10.1016/j.kisu.2020.09.001","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 2","pages":"Pages e97-e185"},"PeriodicalIF":5.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2020.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38361027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 69
Title Page 标题页
IF 5.5 2区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney International Supplements
Pub Date : 2020-12-01 DOI: 10.1016/S2157-1716(20)30026-5
{"title":"Title Page","authors":"","doi":"10.1016/S2157-1716(20)30026-5","DOIUrl":"https://doi.org/10.1016/S2157-1716(20)30026-5","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"10 2","pages":"Page A3"},"PeriodicalIF":5.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(20)30026-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72026892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Kidney International Supplements
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1